NCM
IKT icon

Nantahala Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Nantahala Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.54M Sell
2,701,863
-1,227,429
-31% -$2.18M 0.17% 104
2025
Q4 		$8.06M Buy
3,929,292
+1,739,292
+79% +$2.77M 0.27% 84
2025
Q3 		$3.55M Hold
2,190,000
– – 0.12% 116
2025
Q2 		$4.27M Hold
2,190,000
– – 0.17% 98
2025
Q1 		$4.8M Hold
2,190,000
– – 0.19% 74
2024
Q4 		$7.12M Buy
+2,190,000
New +$5.46M 0.31% 61

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nantahala Capital Management's IKT Position: Q1 2026 in Review

Nantahala Capital Management reduced its Inhibikase Therapeutics (IKT) stake by 31% in Q1 2026, selling an estimated $2.18M and leaving 2,701,863 shares worth $4.54M. The position accounts for 0.17% of the portfolio, ranked #104.

Nantahala Capital Management first reported a position in IKT in Q4 2024 and has held it in 6 quarters since. The position peaked at $8.06M in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Nantahala Capital Management held 2,701,863 shares of Inhibikase Therapeutics worth $4.54M as of Q1 2026.
  • Nantahala Capital Management sold 1,227,429 Inhibikase Therapeutics shares in Q1 2026, an estimated $2.18M.
  • Inhibikase Therapeutics made up 0.17% of Nantahala Capital Management's portfolio in Q1 2026, its #104 holding.
  • Nantahala Capital Management first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Nantahala Capital Management's Inhibikase Therapeutics position peaked at $8.06M in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.